Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)

NCT02731742 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

14

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated early due to business reasons.

Conditions

Neoplasms, Advanced

Interventions

BIOLOGICAL: MK-1966
DRUG: SD-101

Sponsor

Merck Sharp & Dohme LLC